Atea Pharmaceuticals, Inc. (AVIR) Wednesday revealed that its Phase 2 study of Bemnifosbuvir and Ruzasvir Regimen for the treatment of Hepatitis C Virus or HCV achieved primary endpoint of safety and sustained virologic response.
In the pre-market session, AVIR shares reached $3.67, up 0.19 points or 5.46 percent from the previous close of $3.48.
The study showed 98% sustained virologic response at 12 weeks post-preatment, after eight weeks of treatment. In the Phase 2 study, 99% of non-cirrhotic and infected with genotypes 1-4 achieved SVR12, while the treatment adherent patients with cirrhosis achieved a 88% SVR12 rate. The global Phase 2 study has enrolled 275 treatment-naïve patients, both with and without compensated cirrhosis.
The clinical-stage biopharmaceutical company further expects initiation of the global Phase 3 Program early in 2025.
Bemnifosbuvir is a nucleotide analog polymerase inhibitor, and Ruzasvir is an NS5A inhibitor.
Atea said the regimen was "generally safe and well-tolerated with no drug-related serious adverse events or treatment discontinuations."
For comments and feedback contact: editorial@rttnews.com
Business News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.